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ABSTRACT
Psoriasis is an immune-mediated disease that
affects 1%–2% of the European and North
American population. While topical agents
such as corticosteroids and vitamin D
derivatives are prescribed for mild disease, they
are generally unable to adequately control
patients with more severe disease. Over
the past decade, research into the
immunopathogenesis of psoriasis, including
investigations into the role of tumor necrosis
factor-alpha and more recently interleukins (IL)
12/23, has led to the advent of targeted biologic
therapies based on the central role of a new
subset of T cells, Th17. Because of their increased
specificity, biologic agents have revolutionized
short- to medium-term treatment outcomes and
safety profiles for moderate to severe disease
over previously gold standard systemic agents.
The immunopathogenesis of the disease is still a
focus for researchers and novel targets for future
agents are being discovered and investigated in
clinical trials. In particular, specifically targeting
the IL-23/Th17 pathway has given rise to IL-
23p19 and IL-17 antagonists, both of which
have shown significant promise in clinical trials.
IL-22 is involved in keratinocyte proliferation
and is being studied as a treatment target for
psoriasis. New small molecule oral agents,
including Janus kinase and phosphodiesterase
inhibitors are currently in phase 2 and 3 clinical
trials.
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INTRODUCTION
Psoriasis is an inflammatory disease that affects
1–2% of the European and North American
populations [1]. It typically presents with
erythematous, scaly, raised, well-demarcated
lesions on the scalp, trunk, and extensor
surfaces; however, any body site can be
involved. Up to 30% of patients suffer from an
associated arthritis, known as psoriatic arthritis
[2], and patients with more extensive disease
have diminished quality of life because of their
skin and joint disease [3]. Furthermore, there are
genetic links with conditions such as Crohn’s
disease as well as associations with obesity, type
2 diabetes, and cardiovascular mortality.
Current work is attempting to establish if
psoriasis is a specific risk factor per se for these
conditions or if factors such as increased
smoking and alcohol use in patients with
psoriasis accounts for such associations [4, 5].
Typically, topical agents are first-line therapy
for patients with mild psoriasis but generally
ineffective for patients with more severe disease
where a range of therapies, including
phototherapy, systemic, and/or biological
agents are often used. Current gold standard
biologic therapies targeting anti-tumor necrosis
factor (TNF) alpha and anti-interleukin-12p40
(anti-IL-12p40) have dramatically improved
clinical outcomes in patients with psoriasis
with improved short-term safety profiles (i.e.,
less organ specific toxicity) compared to widely
used systemic agents. Despite this
improvement, there are subpopulations of
patients that are either nonresponders to
currently available biological agents and/or
have experienced diminishing therapeutic
benefit over time [6, 7]. Moreover, current
biologic agents still have the potential to cause
significant side effects in a subset of patients
with their longer-term safety yet to be fully
evaluated [8].
Therefore, researchers continue to try and
further elucidate the immunopathogenesis of
psoriasis in an attempt to develop new
therapeutic agents, including newer oral
agents, a method of administration preferred
by some patients. The purpose of this article is
to review new therapeutic avenues, including
anti-IL23, IL-17, and IL-22 antagonists and oral
agents, including Janus kinase (JAK) and
phosphodiesterase 4 (PDE4) inhibitors.
METHODS
A search for phase 1–3 clinical trials for treatment
of moderate to severe chronic plaque psoriasis
using agents targeting IL-23, IL-17, and IL-22
antagonists and oral agents, including JAK and
PDE4 inhibitors, was performed in a
nonsystematic fashion. Eligible participants with
moderate to severe chronic plaque psoriasis
typically include patients with C10% Body
Surface Area (BSA), C12 Psoriasis Area and
Severity Index (PASI) and are candidates for
phototherapy and/or systemic therapy. Patients
withnon-plaque forms of psoriasis were excluded.
TUMOR NECROSIS FACTOR ALPHA
INHIBITORS
The TNF-alpha pathway is an established target
for psoriasis and psoriatic arthritis therapies,
with current licensed anti-TNF medications
including infliximab, adalimumab, and
etanercept. Anti-TNF agents have been used to
treat over 2 million patients with immune-
mediated diseases for extended durations. Thus
its use in psoriasis has been well studied and
new agents are still being developed.
Certolizumab-pegol is a fragment antigen
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binding segment of an anti-TNF antibody and
pegylated to allow for a longer half-life. In phase
2 clinical trials for the treatment of psoriasis,
patients randomized to 400 mg every other
week and 200 mg every other week showed
PASI 75 response in 82.8% and 74.6% of
patients respectively [9]. Golimumab, a newer
anti-TNF therapy, with a license for psoriatic
arthritis, does show efficacy in the treatment of
psoriasis. Phase 3 data demonstrated PASI 75
response in patients receiving 50 or 100 mg of
golimumab every 4 weeks. PASI 75 response in
50 and 100 mg were seen in 40% and 58%
respectively compared to 3% in placebo at week
14 and 56% and 66% respectively, compared to
1% of placebo group seen at week 24 [10].
ART621, a low molecular weight anti-TNF
agent, consists of two identical antibodies and
is believed to have improved tissue penetration.
In a phase 2 study for treatment in plaque
psoriasis, four subjects showed a PASI 50
response in a 12-week treatment period
compared to zero in the placebo arm [11].
INTERLEUKINS 12 AND 23
IL-23 is a heterodimer consisting of a p19 and a
p40 subunit. IL-23 regulates Th17 CD4 cells,
which produce IL-17, a proinflammatory
cytokine [12]. IL-12 is a heterodimer
containing a p35 and p40 subunit. Production
of IL-12 by phagocytes and dendritic cells links
innate and adaptive immunity and activates
signal transducer and activator of transcription
4 (STAT4), which increases the production of
interferon gamma [1]. Studies have shown that
in psoriatic lesions there is an overexpression of
both IL-12 and IL-23. Many of these studies,
however, used the presence of the shared p40
subunit to measure the expression of IL-12 and
thus were unable to differentiate between the
presence of IL-12 and IL-23 [13–16].
Ustekinumab is a human immunoglobulin
G1kappa monoclonal antibody to the p40
subunit, and therefore inhibits the actions of
IL-12 and IL-23 (Table 1) [9–11, 17–22]. Phase 2
randomized controlled trials of 146 patients
with psoriatic arthritis showed that 42% of
subjects achieved an American College
of Rheumatology-20 response at 12 weeks
(Table 1), whereas only 14% of placebo-treated
patients achieved similar results [17]. Phase 3
trials for psoriatic arthritis are ongoing. In
randomized phase 3 trials involving 1,966
patients with psoriasis, 74%–77% of patients
achieved a PASI 75 response after 12 weeks
(Table 1) [23]. During these trials, 55% of
patients experienced one or more adverse
event compared to 50% of patients dosed with
placebo [23]. Major adverse cardiovascular
events (MACE) were also reported during these
trials, predominantly in the initial 12 weeks of
therapy.
Briakinumab is a human anti-IL-12/23
antibody composed of the p40 subunit with
human monoclonal IgG1 heavy chain bound to
human monoclonal lambda light chain
(Table 1). During four phase 3 studies, a PASI
75 response was seen in 81.9%, 81.8%, 80.7%,
and 80.6% of briakinumab-treated patients at
12 weeks, respectively (Table 1). In the phase 2
and 3 extension studies, 99% of patients
showed PASI 75 at 48 weeks, and 76% showed
PASI 100 at week 24. In phase 3 studies,
however, five MACE occurred in the group
receiving briakinumab versus none in those
taking placebo. Twenty-one additional MACE
occurred during the phase 2 and 3 extension
trials. Because of these events, in July 2011
Abbott withdrew its application for drug
approval from the FDA and EMA. This also led
to investigation into the relationship between
anti-IL-12/23 therapies and vascular
inflammation. During the phase 2 and 3 trials
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of ustekinumab, 10 MACE occurred compared
to zero MACE in the placebo-treated patients
[18]. However, further studies investigating the
relationship and specific mode of action of
these agents relating to coronary artery
atherosclerosis and inflammation are still
needed to draw conclusions that are more
definitive.
More recently, a study showed an increase in
RNA expression of the IL-23p19 subunit in
psoriatic lesions, but no increase in the
expression of the p35 subunit found in IL-12
[16]. These data suggest that IL-23 may be more
influential in maintaining psoriatic lesions than
IL-12. Furthermore, it has been shown that
IL-23 drives keratinocyte proliferation to a
greater extent than IL-12 [24]. These
observations have led to the development of
agents that target the p19 subunit of IL-23.
BI655066 (BI) is a humanized IgG1 monoclonal
antibody that binds and neutralizes the p19
subunit of IL-23 and is currently in phase 1 trials
(Table 1). Merck’s (Merck & Co., Inc,
Whitehouse Station, NJ, USA) SCH 900222 is
also an anti-IL-23 antibody that targets the p19
subunit. It is currently in phase 2 trials for
psoriasis (Table 1) and phase 3 trials are
imminent.
INTERLEUKIN-17
While IL-23 is believed to be a key initiating
cytokine in the development and maintenance
of Th17 cells and a proven and effective target for
psoriasis therapies, inhibiting the Th17
component of the IL-23/Th17 axis has also
shown promising results [25]. The innate
immune system release cytokines in response
to environmental triggers, which leads to
activation of myeloid dendritic cells. Myeloid
dendritic cells, in turn, secrete IL-23, which
drives Th17 differentiation (Fig. 1). Th17 cells
produce IL-22 and IL-17, a family of six cytokines
(A–F) and five receptors, the levels of which have
been shown to be increased in psoriatic skin [26]
(Fig. 1). IL-17 is proinflammatory and induces
the expression of cytokines, which result in
keratinocyte proliferation and epithelial cell
inflammation in psoriasis. Increased IL-17
levels lead to an increase in neutrophil
migration and survival in the dermis in
addition to driving angiogenesis [26].
Brodalumab is a human monoclonal IgG2
antibody that antagonizes the IL-17 pathway by
targeting and binding human IL-17A receptor
and thus blocking the activity of IL-17A, IL-17F,
and IL-17A/F [19]. An initial phase 1 study
of 700 mg brodalumab administered
intravenously in 10 patients showed
significant clinical improvement at 6 weeks.
A phase 2 double-blind, placebo-controlled,
dose-ranging study in 198 patients with
chronic plaque psoriasis also showed
significant improvement at 12 weeks. Patients
were randomized to placebo, 70, 140, and
210 mg administered biweekly, or 280 mg
administered monthly and were shown to
have mean PASI improvements of 16.0%,
45.0%, 85.9%, 86.3%, and 76.0%, respectively
[19]. Two cases of neutropenia were reported in
the 210 mg brodalumab group. Adverse events
included nasopharyngitis, upper respiratory
Fig. 1 Relationship between IL-23, Th17 cells, IL-22, and
IL-17. IL Interleukin, Th T-helper
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tract infection, and injection site erythema [19].
Multiple phase 2 extension studies are ongoing
and a phase 3 study comparing safety and
efficacy of brodalumab to ustekinumab and
placebo is to begin soon.
Secukinumab is a human monoclonal IgG1
antibody that targets the IL-17A cytokine. In an
initial proof of concept study in 36 patients,
3 mg/kg secukinumab administered
intravenously demonstrated efficacy at 4 weeks
and sustained efficacy at 12 weeks. In an
ongoing phase 2 randomized, placebo-
controlled trial with active arms, including
subcutaneous doses of 150 mg one-time,
150 mg monthly, and 150 mg at weeks 1, 2,
and 4, PASI 75 improvements were seen in 12%,
43%, and 54.5% compared to just 5% in the
placebo arm. A current phase 3 study is ongoing
comparing 150 and 300 mg subcutaneous
secukinumab doses to placebo. Treatment and
placebo groups demonstrated similar safety
profiles [20, 27].
Ixekizumab is a human IgG4 monoclonal
antibody targeting IL-17A cytokine. In a phase
2 study, 142 patients were randomized to
placebo, 10, 25, 75, and 150 mg subcutaneous
doses of the ixekizumab [21]. Impressive PASI
75 responses were seen in 76.7%, 82.8%, and
82.1% of patients receiving 25, 75, and 150 mg
dosages respectively, compared to only 7.7% of
patients receiving placebo [21]. No serious
adverse or cardiovascular events were
observed. A phase 3 study comparing safety
and efficacy to etanercept and placebo will
begin this year.
INTERLEUKIN-20/22
Although the immunopathogenesis of psoriasis
through the Th17/IL-23 axis has been a primary
focus for investigators, mechanisms inherent to
keratinocyte proliferation and epidermal
hyperplasia are also being studied. The IL-10
family of cytokines, specifically IL-20 and IL-22,
play an integral role in this process by causing
proliferation and altering differentiation
of keratinocytes [28]. Additionally, IL-22
expression activates STAT3, which mediates
acanthosis, a characteristic histologic finding
in psoriasis lesions. Th17 cells secrete IL-22
(Fig. 1), which can induce expression of IL-20
that then acts as a secondary mediator [29].
Thus, the process may also be T cell driven.
These cytokines, which are virtually
undetectable in normal, healthy skin, are
expressed at increased levels in psoriatic
lesions [28]. Elevated levels of IL-22 in the
blood have been correlated with disease
severity.
Fezakinumab is a humanized monoclonal
IgGy antibody to IL-22 being studied for
treatment in rheumatoid arthritis and
psoriasis. Safety and tolerability results of
phase 1 trials for moderate to severe psoriasis
are to be published in the near future [11].
JANUS KINASE INHIBITORS
Cytokines that target STAT transcription factors
activate JAK, a type of tyrosine kinase. By
inhibiting JAK, the inflammatory action of T
cells and cytokines such as IL-2, -6, -7, -9, -15,
and -21 and interferons are suppressed.
Tofacitinib is a JAK inhibitor that targets JAK1
and JAK1/JAK3 specifically. It was developed as
an immunosuppressant to treat rheumatoid
arthritis, ulcerative colitis, Crohn’s disease,
and psoriasis, and to prevent transplant
rejection [30]. In a phase 2a study of
tofacitinib involving 59 patients with psoriasis,
twice daily doses of 5, 10, 20, and 50 mg and
once-daily doses of 60 mg of oral tofacitinib
Page 6 of 10 Dermatol Ther (Heidelb) (2012) 2:16
123
were compared versus placebo [11]. After
14 days of treatment, a dose-dependent
reduction of Psoriatic Lesion Severity Sum
compared to placebo was seen in all patients
except those taking the 5 mg dose. Those
patients taking 50 mg doses of oral tofacitinib
twice daily showed a 71.8% reduction in PASI
(Table 1), whereas the placebo group showed a
PASI reduction of only 11.5%. One hundred
and ninety-seven patients with psoriasis
participated in a subsequent phase 2b study,
during which subjects were given 2, 5, or 15 mg
of oral tofacitinib twice daily [11]. A PASI 75
response was seen in 25%, 40.8%, and 66.7%
respectively. Of those treated with placebo, only
2% achieved a PASI 75 response. Phase 3 studies
in psoriasis using up to 10 mg twice daily dosing
are currently being performed to confirm safety
and efficacy [31] (Table 1).
Baricitinib is an oral drug that selectively
inhibits JAK1 and JAK2. During phase 1 studies,
baricitinib was shown to be safe and well
tolerated in 1–20 mg single doses and repeat
doses of 2–20 mg. Current phase 2 trials are
being performed to determine the efficacy of
the drug, the effects of discontinuation, and the
safety and efficacy of retreatment (Table 1).
ASP-015K (Astellas Pharma US, Inc.,
Northbrook, IL, USA) is a JAK 3 inhibitor




Through inhibition of PDE4, it is possible to
increase the amount of cyclic adenosine
monophosphate in leukocytes, minimizing
their inflammatory actions such as cytokine
transcription, neutrophil degranulation,
chemotaxis, and adhesion to endothelial cells.
Therefore, PDE4 inhibitors have the potential to
successfully treat immune-mediated disorders
such as psoriasis, rheumatoid arthritis, and
Behc¸et’s disease. Currently, Celgene (Celgene,
Summit, NJ, USA) is developing an oral PDE4
inhibitor, apremilast (CC-10004), to treat
psoriasis and psoriatic arthritis (Table 1). When
tested on mouse models, histological features of
psoriasis and epidermal thickening decreased
significantly. Additionally, expression of TNF-
alpha, intercellular adhesion molecule-1, and
human leukocyte antigen-DR in psoriatic
lesions were reduced. During a phase 2 clinical
trial that involved 260 patients with psoriasis
24.4% of patients taking 20 mg of apremilast
twice daily for 84 days showed a PASI 75 response.
Only 10.3% of those on placebo had the same
results [11]. In a subsequent phase 2b study,
patients with psoriasisweregiven10, 20, or 30 mg
doses of apremilast twice daily. PASI 75 was seen
in 11%, 29%, and 41%, respectively (Table 1). In
this study, which involved 352 patients with
moderate to severe psoriasis, eight serious adverse
events occurred. None of these serious adverse
events, however, were thought to be caused by
apremilast [22]. Phase 3 trials are now being
performed to test the safety and efficacy of two
30 mg doses of apremilast per day for 16 weeks.
Apremilast’s potential for treatment of
palmoplantar psoriasis and psoriatic arthritis are
also being researched in phase 2 and phase 3
studies, respectively (Table 1) [11].
CONCLUSION
Through increased understanding of the
immunopathogenesis of psoriasis, major
advances are continuing to be made in the
realm of new biologic and oral treatments for
plaque psoriasis. Specifically, the Th17/IL-23
axis has been a focus for investigators,
Dermatol Ther (Heidelb) (2012) 2:16 Page 7 of 10
123
resulting in many novel agents currently in
clinical trials. The IL-23p19 inhibitors are of
particular interest in targeted therapies as they
are present at increased levels in psoriasis skin
lesions and believed to contribute less in
protecting against opportunistic infections and
less likely to be responsible for MACE events
than its IL-12 counterpart. Other cytokines such
as IL-17 and IL-22 also play important roles in
the pathogenesis of psoriasis and agent’s
inhibition of them has shown promising
results [26, 28]. Moreover, oral agents such as
JAK kinase and PDE4 inhibitors have proven
effective in phase 2 and 3 clinical trials with a
different safety profile and may offer options to
patients averse to injectable agents. It is
important to note, however, these new agents
are potentially immunosuppressive and some
are already known to increase the risk of serious
infections. There is a need to be vigilant for
longer-term side effects, including the potential
for an increased risk of malignancy, the best
method of doing so via established
pharmacovigilance registries [32].
Times are promising in the field of targeted
therapies for psoriasis, and continued research
into the immunopathogenesis of the disease
will only lead to a growing armamentarium of
safe and effective therapeutic agents.
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